ABT
Abbott Laboratories NYSE$87.58
Mkt Cap $152.5B
52w Low $87.30
0.5% of range
52w High $139.06
50d MA $104.06
200d MA $120.55
P/E (TTM)
23.9x
EV/EBITDA
19.5x
P/B
3.0x
Debt/Equity
0.3x
ROE
12.1%
P/FCF
29.6x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$104.06
200d MA
$120.55
Avg Volume
11.7M
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, ir…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | AMC | 1.14 | 1.15 | +0.9% | 95.47 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% | — | — |
| Jan 22, 2026 | AMC | 1.50 | 1.50 | +0.0% | 108.61 | -0.3% | -1.1% | +0.1% | -0.3% | -2.4% | -2.3% | +6.2% | — |
| Oct 15, 2025 | AMC | 1.30 | 1.30 | +0.0% | 129.45 | +0.1% | -1.4% | -0.7% | +0.0% | -1.5% | -1.2% | +0.9% | — |
| Jul 17, 2025 | AMC | 1.26 | 1.26 | +0.0% | 120.51 | +1.8% | +2.6% | +3.2% | +4.3% | +4.4% | +4.3% | +8.1% | — |
| Apr 16, 2025 | AMC | 1.07 | 1.09 | +1.9% | 129.70 | +0.5% | +1.0% | +0.1% | +1.6% | +0.1% | -0.2% | +3.9% | — |
| Jan 22, 2025 | AMC | 1.34 | 1.34 | +0.0% | 117.78 | +0.3% | +4.6% | +6.2% | +9.9% | +8.2% | +8.6% | +14.6% | — |
| Oct 16, 2024 | AMC | 1.20 | 1.21 | +0.8% | 117.82 | +0.8% | +0.1% | +1.3% | -0.7% | -1.4% | -0.7% | -1.6% | — |
| Jul 18, 2024 | AMC | 1.10 | 1.14 | +3.6% | 100.07 | +0.5% | +2.0% | +3.6% | +3.8% | +7.2% | +5.9% | +11.8% | — |
| Apr 17, 2024 | AMC | 0.95 | 0.98 | +2.6% | 105.90 | +0.6% | -0.6% | +1.3% | +1.1% | +1.6% | +0.9% | -1.7% | — |
| Jan 24, 2024 | AMC | 1.19 | 1.19 | +0.0% | 110.77 | +0.6% | +1.5% | +1.1% | +2.4% | +2.4% | +2.1% | +7.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | BTIG | Maintains | Buy → Buy | — | $91.13 | $91.62 | +0.5% | +1.8% | +3.0% | +0.2% | -0.4% | -1.8% |
| Apr 22 | Daiwa Securities | Downgrade | Outperform → Neutral | $92 | $92.72 | $92.62 | -0.1% | -1.1% | -0.3% | -1.7% | +0.1% | +1.2% |
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $96.81 | $96.50 | -0.3% | -0.8% | -4.2% | -5.3% | -4.5% | -5.9% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | BTIG | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | Stifel | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | Benchmark | Maintains | Buy → Buy | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
| Apr 17 | Evercore ISI | Maintains | Outperform → Outperform | — | $95.47 | $95.62 | +0.2% | +1.4% | +0.6% | -2.9% | -3.9% | -3.1% |
Recent Filings
8-K · 5.02
!!! Very High
Abbott Laboratories -- 8-K 5.02: Executive Change
Apr 27
8-K · 8.01
!! High
Abbott Laboratories -- 8-K 8.01: Material Event / Announcement
Abbott settled six shareholder derivative lawsuits related to its infant formula crisis for an undisclosed amount, with the settlement requiring court approval and potentially affecting director and officer liability exposure.
Apr 17
8-K
Unknown — 8-K Filing
Abbott is reminding investors that management relies on non-GAAP metrics internally, but GAAP results should remain primary—suggesting actual reported earnings may look weaker than management's preferred performance measures.
Apr 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of an executive effective April 15, 2026 signals potential leadership uncertainty; investors should monitor whether the replacement demonstrates strategic continuity or signals broader organizational concerns affecting these companies' performance.
Apr 14
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott's failure to promote Teplitsky to COO signals internal management instability and potential leadership challenges, which could concern investors about strategic direction and executive bench strength.
Apr 9
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
Abbott has completed a significant acquisition, likely expanding its product portfolio and market reach, which could drive revenue growth and shareholder value if the target company's assets integrate successfully.
Mar 23
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Abbott Laboratories announced a significant transaction with Exact Sciences Corporation on March 23, 2026, potentially indicating a major acquisition or partnership that could reshape its diagnostic business and impact future growth prospects.
Mar 23
8-K
Unknown — 8-K Filing
Abbott's acquisition of Exact Sciences faces material business risks that could impact integration success and profitability, warranting investor scrutiny of synergy realization and operational challenges ahead.
Mar 20
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K · 1.01
! Medium
Abbott Laboratories -- 8-K 1.01: Financing / Debt Agreement
Abbott Laboratories issued debt notes through underwriters Morgan Stanley, Barclays, and BofA Securities, expanding its financing capacity for future operations and strategic investments.
Mar 9
Data updated apr 24, 2026 10:18am
· Source: massive.com